Skip to main content

Aczone, A Topical Gel Formulation Of The Antibacterial, Anti-Inflammatory Dapsone For The Treatment Of Acne

Allergen Inc has launched Aczone, a topical gel formulation of the antibacterial, anti-inflammatory agent dapsone, for the potential treatment of acne vulgaris.

Oral dapsone has demonstrated efficacy in acne, but was associated with severe side effects such as anemia, which was particularly serious in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Aczone was developed to overcome this limitation, and is formulated using solvent-microparticle technology for improved absorption and action and for fewer side effects. In a phase I clinical trial, systemic exposure to dapsone was 126-fold lower following treatment with Aczone compared with oral dapsone.

Aczone significantly reduced lesion counts in patients with acne in phase III trials, and was particularly effective in reducing inflammatory lesions. In a phase IV trial, Aczone was safely applied to patients with G6PD deficiency without inducing anemia.

Phase IV trials in patients with acne were ongoing at the time of publication to assess safety and to compare Aczone monotherapy with combinations of Aczone and other anti-acne therapeutics.

At the time of publication, Allergen was also developing Aczone for the treatment of rosacea; the drug was undergoing phase II trials for this indication. Aczone appears to be a novel promising anti-acne therapeutic option, particularly for patients with inflammatory acne.


"Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne"
Scheinfeld N
Curr Opin Investig Drugs. 2009 May ; 10(5): 474-81 (Hubmed.org)




Highlight :
Treatment Of Rosacea | Acne Rosacea Antibiotic

Popular posts from this blog

Prevalence Of And Associated Factors For Dry Eye In A Spanish adult population

To estimate the prevalence of dry eye and to investigate its relationship with lifestyle and systemic factors in a general adult population in north-western Spain. METHODS: A dry eye questionnaire was administered and objective tests were performed in 654 individuals [mean age (Standard deviation): 63.6 (14.4) years, range: 40-96, 37.2% males]. Subjects were considered symptomatic when one or more of the symptoms of the questionnaire were present often or all the time. Schirmer test or= 3 and fluorescein staining >or= 1 were considered indicative of signs. Dry eye was defined as the simultaneous presence of symptoms and at least one sign. A design based analysis was performed and all calculations were weighted to give unbiased estimates. RESULTS: Dry eye prevalence was 11.0% (95%confidence interval [CI] 8.6-13.3). Dry eye was found to be more frequent in women (11.9%, 95%CI 8.8-15.1) than in men (9.0%, 95%CI 5.3-12.6), and was significantly associated with aging (p autoimmune diseas...

Treatments For Rosacea

The specific treatments for rosacea is determined by your physician based on: Your age, general health and medical history. How advanced is the eruption. Tolerance to specific medications, procedures or therapies. Their expectations for the trajectory of the eruption. Your opinion or preference. Treatments for rosacea may include : Modifications to diet Antibiotics. Cortisone ointment. Laser surgery Use sunscreen with a sun protection factor Currently there are several treatments for rosacea are used, depending on the events that it has. At the initial stage, to prevent the dilation of blood vessels and the consequent need to avoid red hot environments, exposure to sunlight, extreme changes in temperature and food hot or too much seasoning. When pustules that resemble pimples, prescribed oral antibiotics such as tetracycline. Another alternative treatments for rosacea is the topical antibiotics such as metronidazole. Also is using retinoids, which regulate the sebum production of the ...

ATPgammaS enhances the production of inflammatory mediators

Adenosine 5'-triphosphate (ATP) affects multiple intra- and extracellular processes, including vascular tone and immune responses. Microvascular endothelial cells (EC) play a central role in inflammation by recruitment of inflammatory cells from blood to tissues. We hypothesized that ATP (secreted by neurons and/or released after perturbation of cutaneous cells) may influence secretion of inflammatory messengers by dermal microvascular EC through actions on purinergic P2 receptors. Addition of the hydrolysis-resistant ATP analogue, adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), to subconfluent cultures of the human microvascular endothelial cell-1 (HMEC-1) cell line led to a dose- and time-dependent increase in release of IL-6, IL-8, monocyte chemoattractant protein-1, and growth-regulated oncogene alpha. Both ATPgammaS-induced release and basal production of these proteins were significantly inhibited by the purinergic antagonists pyridoxal-5'-phosphate-6-azophenyl-2...